

APPLICATION OF DYNAMIC ARC THERAPY TECHNIQUE FOR TREATMENT OF HEAD AND NECK TUMORS

Presented By

Mohamed Saber Ibrahim

B.Sc. in physics 1999

A thesis submitted as partial fulfillment of the requirement for the degree of Master of Science in Biophysics

Supervised by

Prof. Dr. El-Sayed Mahmoud El-Sayed Prof. Dr. Abdel Sattar Mohamed Sallam

Professor of Biophysics Physics Department Faculty of Science, Ain Shame University Faculty of Science, Ain Shame University

Professor of Biophysics Physics Department

Dr. Mohamed Metwaly Mohamed Consultant Radiotherapy Physics The Beatson West of Scotland Cancer Center

> Ain Shams University Faculty of Science Department of physics (2014)

APPROVAL SHEET

Title of the M.Sc. Thesis

APPLICATION OF DYNAMIC ARC THERAPY TECHNIQUE FOR TREATMENT OF HEAD AND NECK TUMORS

Name of the Candidate

Mohamed Saber Ibrahim El-Basuny

<u>Supervisors</u>		(Signature	<u>:</u>)
Prof. Dr. El-Sayed Mah	moud El-Sayed Professor of Bio	(.)
	Physics Departs	1 0	
	• 1	nce, Ain Shame University	
Prof. Dr. Abdel Sattar I	Mohamed Sallam	(.)
	Professor of Bio	ophysics	
	Physics Departs	ment	
	Faculty of Scient	nce, Ain Shame University	
Dr. Mohamed Metwal	y Mohamed	(.)
	Consultant Rad	iotherapy Physics	•
	The Beatson W	est of Scotland Cancer Cent	er



Name: Mohamed Saber Ibrahim El-Basuny

Degree: Master

Department: Physics-Biophysics Group

Faculty: Science

University: Ain Shams

Graduation Date: 1999

Registration Date: 4/2009

Grant Date: 2014

ACKNOWLEDGEMENT

I wish to express my deep gratitude to **Prof. Dr. EI-Sayed Mahmoud**, Professor of Biophysics, Department of Physics, Faculty of Science, Ain Shame University, for his supervision, advice and reviewing the manuscript.

I wish to express my deep appreciation to **Prof. Dr. Abdel Sattar Sallam**, Professor of Biophysics, Department of Physics, Faculty of Science, Ain Shame University, for his supervision, constructive criticism and deep concern of this work.

I would like to express my gratitude and appreciation to **Dr. Mohamed Metwaly Mohamed,** Consultant Radiotherapy Physics, The Beatson West of Scotland Cancer Center, U.K. for his supervision, advice, critical comments, fruitful discussion, reviewing the manuscript and continuous support.

I would like to introduce my great appreciation to **my colleagues and consultants** in the departments of radiation physics and radiotherapy in Maadi Armed Forces Medical Compound as well as to the family of the department of physics, faculty of science, Ain Shame University, for their encouragement and pushing forward of this work.

Special thanks are directed to all the **members** of my family for their assistance and encouragement.

CONTENTS

Subject Page

LIST OF ABBREVIATIONS1
LIST OF SYMBOLS3
LIST OF FIGURES4
LIST OF Tables10
ABSTRACT11
CHAPTER 1: INTRODUCTION AND AIM OF THE
<u>WORk</u> 13
(1-1) Introduction
Chapter 2: Radiotherapy Technology and Clinical Background on the Head and Neck Canc16
(2-1) Part I RadiotherapyTechnology16
(2-1-1) Linear Accelerator
(2-1-2) Patient immobilization21
(2-1-3) Three Dimensional Conformal Radiotherapy22

(2-1-4) Intensity Modulated Radiotherapy25
(2-1-5) Arc therapy26
(2-1-6) Electronic Portal Image Device27
(2-1-7) The Radiotherapy Network
(2 1 /) The Rudiotherapy Protivork
(2-2) Part II Clinical Background on the Head and
Neck tumors30
(2-2-1) Head and Neck Anatomy30
(2-2-2) What is the Nasopharyngeal cancer?32
(2-2-3) Risk Factors
(2-2-4) Symptoms of Nasopharyngeal cancer
(2-2-5) Diagnosing of Nasopharyngeal Cancer36
(2-2-6) Grading and Staging of Nasopharyngeal Cancer38
(2-2-7) Prognosis of untreated Nasopharyngeal Canc41
(2-2-8) Nasopharyngeal Cancer treatment options42
Chapter 3: Literature Review on Radiotherapy Planning
Techniques of Head and Neck Cancer47
(0.4) 0 I.B. II. II. BI. I.
(3-1) Conventional Radiotherapy Planning
Techniques 47
(3-2) Three Dimensional Conformal Radiotherapy, 3D-
CRT
(3-3) Intensity Modulated Radiotherapy, IMRT51
Chapter 4: Materials and Methods61
(4-1) Patient Positioning and Immobilization62
(4-1) Patient Positioning and Immobilization

(4-9) Plans verification	69
Chapter 5: Results, Discussion and Conclusion	73
(5-1) Part I: Results and discussion of the treatme techniques of nasopharyngeal carcinoma	
(5-1-1) W-DAT plan optimization	
(5-2) Part II: Dosimetric verification of the W-DAT	
(5-3) Conclusion	
SUMMARY	95
REFERENCES	97
ملخص الرسالة	1

List of Abbreviations

3D-CRT: Three-dimensional conformal radiation therapy.

CT: Computed tomography.

CTV: Clinical target volume.

DD: Dose difference.

DI: Dose inhomogeneity.

DTA: Distance to agreement.

DVH: Dose volume histogram.

EDR: Extended dose range.

EWF: Extend whole field.

GTV: Gross target volume.

HB-IMRT: Half beam intensity-modulation radiation therapy.

HT: Helical tomotherapy.

FP-IMRT: Forward planning intensity-modulation radiation therapy.

IMRT: Intensity-modulation radiation therapy.

IP-IMRT: Inverse planning intensity-modulation radiation therapy.

MLC: Multileaf collimator

OAR: Organs at risk.

PRV: Planning risk volumes.

PTV: Planning target volume.

PTV1: Sites of gross disease (primary tumor).

PTV2: Site of microscopic disease (upper and lower neck).

SF: Split Field

VBV: Virtual brain stem volume.

VMAT: Volumetric modulated arc therapy.

VMAT-S: Volumetric modulated arc therapy with smart arc.

WB-IMRT: Whole beam intensity-modulation radiation therapy.

W-DAT: Wedged dynamic arcs therapy.

List of Symbols

D_{max}: Maximum dose to any volume.

 D_{mean} : Mean dose to any volume.

D_{median}: Median dose to any volume.

 D_{min} : Minimum dose to any volume.

 D_{modal} : Modal dose to any volume.

DV%: Dose that covers Vx % of any volume, as obtained from the mean dose volume histograms.

VD%: Volume that is covered by Dx % of the prescribed dose (78 Gy), as obtained from the mean dose volume histograms.

 V_{Dmax} : Volume that is covered by the maximum dose.

 V_{Dmin} : Volume that is covered by the minimum dose.

List of Figures

Chapter 2.	Radiotherapy Technology and Clinical	Page.
	Background on the Head and Neck Cancer	
Figure 2.1	Dual photon energy linear accelerator manufactured by	17
	Varian (model 23EX), Palo Alto, California; the gantry,	
	Collimator, treatment couch and portal vision device are	
	clearly shown.	
Figure 2.2	A schematic diagram represents: (a) the normal jaws of the	20
	collimator which do not match the tumor shape (b) the MLC	
	leaves that give the shape of the tumor.	
Figure 2.3	An immobilized patient by a head and neck thermoplastic	21
	mask.	
Figure 2.4	The beam eye view (BEV) of an anterior field for a case of	24
	head and neck tumor including clinical target volume CTV	
	(red), spinal cord (yellow), Lt eye (brown), Rt eye (blue), Lt	
	parotid (green), Rt parotid (pink), Neck node (Cyan) and	
	temporomandibular joint (translucent yellow).	
Figure 2.5	Head and Neck anatomy.	32

Chapter 3.	Review on Radiotherapy Planning Techniques	Page.
	of Head and Neck Cancer	
Figure 3.1	(a) The 2-field beam arrangement with open fields, (b)	48
	spinal cord shielded fields [Fletcher and Million, 1980].	
Figure 3.2	3-field beam arrangement [Fletcher and Million, 1980].	49
Figure 3.3	The field portals used for treatment of the (a) anterior and	49
	(b) posterior lower neck lymphatics.	
Figure 3.4	A 7-field arrangement.	50
Figure 3.5	Spilt field (SF) technique	55
Figure 3.6	Extend whole field (EWF) technique	56

Chapter 4.	Materials and Methods	Page.
Figure 4.1	Fields arrangement and isodose distribution for wedged	65
	dynamic arc therapy technique in (a) transversal, (b) frontal,	
	(c) sagittal and the (d) dose-volume histograms for site of	
	gross disease (PTV1), microscopic disease (PTV2) and	
	organs at risk.	
Figure 4.2	(a) The two anterior-posterior conformal fields conforming	66
	to the beam's eye view of site of gross disease (PTV1). (b)	
	Another two anterior-posterior conformal fields conforming	
	to the beam's eye view of site of microscopic disease	
	(PTV2).	
Figure 4.3	A photograph shows the positioning of the cylindrical	70
	phantom in which a pinpoint ion chamber is located for	
	isocenteric dose measurements.	
Figure 4.4	A photograph shows the positioning of the 30 x 30 x 30 cm	71
	Solid Water slab phantom in which a EDR2 film is inserted	
	during film calibration.	
Figure 4.5	A photograph shows the positioning of the Alderson	72
	phantom in which Kodak EDR2 films are inserted at two	
	levels located in the regions of the site of gross disease	
	(PTV1) and microscopic disease (PTV2)	

Chapter 5.	Results, Discussion, Conclusion and Summary	Page.
Figure 5.1	Dose volume histogram (DVH's) analyses for all sites of gross	74
	disease (PTV1).	
Figure 5.2.a	Dose volume histogram (DVH's) analyses for all sites of RT	75
Figure 5.2.b	neck (PTV2's).	
	Dose volume histogram (DVH's) analyses for all sites of LT	75
	neck (PTV2's).	
Figure 5.3.a	Dose volume histogram (DVH's) analyses for all Rt Parotids.	76
Figure 5.3.b	Dose volume histogram (DVH's) analyses for all Lt Parotids.	76
Figure 5.4	Dose volume histogram (DVH's) analyses for all Brain Stems.	76
Figure 5.5	Dose volume histogram (DVH's) analyses for all Spinal cords.	77
Figure 5.6	Dose volume histogram (DVH's) analyses for all Mandibles.	77
Figure 5.7	Comparison between isodose curves for (a) Intensity-	80
	modulation radiation therapy (IMRT) technique and (b)	
	Wedged dynamic arcs therapy (W-DAT) technique displayed	
	on the axial, coronal and sagittal planes through the centroid	
	of the primary tumor and the Dose volume histogram (DVH)	
	.for the relevant structures.	

		0.2
Figure 5.8	Comparison between isodose distribution for (a) Intensity-	82
	modulation radiation therapy (IMRT) (b) Volumetric modulated	
	arc therapy with smart arc (VMAT-S) (c) Helical tomotherapy	
	(HT) and (d) Wedged dynamic arcs therapy (W-DAT)	
	technique.	
Figure 5.9	Comparison between isodose curves for (a) Rapidarc technique	86
	and (b) Wedged dynamic arcs therapy (W-DAT) technique	
	displayed on the axial, coronal and sagittal planes through the	
	centroid of the primary tumor and the Dose volume histogram	
	.(DVH's) for the relevant structures.	
Figure 5.10.a	Deviation between the measured and calculated dose for	89
	nasopharynex level.	
Figure 5.10.b	Deviation between the measured and calculated dose for brain	89
	stem level.	
Figure 5.11	Example of gamma index distributions for measured and	90
	calculated dose distributions for the nasopharynx level.	
Figure 5.12	Example of gamma index distributions for measured and	91
	calculated dose distributions for the neck node level.	
Figure 5.13	Failed pixels percentage in wedged dynamic arc dose	92
	distribution as compared with the gamma acceptance criteria	
	(3% dose difference and 3 mm distance to agreement) for	
	nasopharynx level.	
	1	